ATS found out the hard way in a long clinical trial that if tissue metabolic activity was not within a certain range, healing suffered. ATS also makes and markets TransCyte, which is a temporary skin for partial thickness burns, to help new cells grow. Dermagraft is a total skin replacement for full thickness burns and chronic wounds like diabetic foot ulcers. The evidence ATS provides is inspiring. Patients on whom Dermagraft is used have shown reduction of pain within 30 minutes, and can be released from the hospital within one or two days rather than the 10 to 12 typically needed for healing.
Pictures show cosmetic improvement in days.
ATS has a British partner, Smith and Nephew. According to ATS, applications of skin scaffold tissue are more widely applied in Britain than in the United States because of differing medical regulations. Getting Under the Skin Naughton told the gathering in Washington that wound healing is just the beginning for tissue engineering. ATS has developed bioreactors and methods of producing implants for human cartilage, blood vessels, bone, ligaments, even liver and pancreatic tissue. The cartilage produced in bioreactors can be used for orthopedic repair and facial reconstruction.